A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

开始日期2025-10-03

申办/合作机构

Pfizer Inc.

NCT05685264

/ Completed临床1期

A PHASE 1, OPEN-LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF PONSEGROMAB ADMINISTERED SUBCUTANEOUSLY IN HEALTHY ADULT CHINESE PARTICIPANTS

The purpose of this clinical trial is to learn about the safety of the study medicine (ponsegromab) and how it undergoes change and elimination in healthy Chinese adults. This study is seeking male and female Chinese participants who are very healthy as confirmed after some medical tests.
All participants in this study will receive Ponsegromab only once:
* for half of the participants, ponsegromab will be given as a shot in the front of the thigh, abdomen, or outer area of the upper arm at the study clinic.
* for another half of the participants, ponsegromab will be given as four shots in the front of the thigh, abdomen, or outer area of the upper arm at the study clinic.
We will measure the amount of the study medicine in the blood of the participants after giving the shots. Later we will examine experiences of people receiving the study medicine. This will help us understand how the medicine is changed and eliminated from your body and to decide if the study medicine is safe. Participants will take part in this study for 22 weeks. During this time, they will stay at the study clinic for the first 8 days and will visit the study clinic about 8 times.

开始日期2023-01-18

申办/合作机构

Pfizer Inc.

NCT05546476

/ Completed临床2期

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

开始日期2022-11-21

申办/合作机构

Pfizer Inc.

100 项与珀塞古单抗相关的临床结果

登录后查看更多信息

100 项与珀塞古单抗相关的转化医学

登录后查看更多信息

100 项与珀塞古单抗相关的专利（医药）

登录后查看更多信息

项与珀塞古单抗相关的文献（医药）

2025-08-31·Journal of bone metabolism

Latest Updates on Sarcopenia and Cachexia: Insights from the 17th Sarcopenia, Cachexia, and Wasting Disorders Conference

Article

作者: Kim, Hyeon Su ; Park, Hyunwoo ; Gu, Bon-Sang ; Kim, Hyunbin ; Yoo, Jun-Il

The 17th Sarcopenia, Cachexia, and Wasting Disorders Conference, held from December 6 to 8, 2024, in Washington, DC, showcased groundbreaking advancements in understanding and managing muscle wasting conditions. Drawing on the lecture notes and presentations of internationally recognized experts who spoke at the meeting, this review highlights key insights and recent developments discussed during the conference. This review focuses on sarcopenia, cancer cachexia, and other wasting disorders linked to chronic diseases. Key discoveries included the identification of the Macroautophagy and YouTH Optimizer pathway in muscle regulation, the role of ectodysplasin A2 receptor-nuclear factor-κB-inducing kinase signaling in muscle atrophy, and the impact of mitochondrial dysfunction on systemic health. Advancements in diagnostic tools, including artificial intelligence-powered imaging and novel biomarkers, are transforming the detection and management of these conditions. Emerging therapeutic strategies, such as glucagon-like peptide 2-based treatments, selective androgen receptor modulators, and cytokine inhibitors, are reshaping the therapeutic landscape. The conference underscored the importance of precision medicine, integrating molecular insights with personalized care approaches, and emphasized multidisciplinary rehabilitation to optimize patient outcomes. The conference also highlighted promising clinical advancements, including the HIPGEN trial on placental-expanded stromal cells for muscle regeneration in hip fracture patients and the ponsegromab study targeting growth/differentiation factor-15 inhibition to mitigate cancer cachexia-associated muscle wasting. This review highlights the integration of basic science, innovative diagnostics, and clinical applications as a promising framework for addressing the complex challenges posed by muscle-wasting disorders. As the field progresses, these insights offer hope for improving the quality of life and survival of affected patients.

2025-06-01·Journal of Cachexia Sarcopenia and Muscle

Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues

Article

作者: Evans, William J. ; von Haehling, Stephan ; Anker, Stefan D. ; Langer, Henning T. ; Heymsfield, Steven B.

ABSTRACT:

In December 2024, the Society on Cachexia and Wasting Disorders (SCWD) hosted a Regulatory and Trial Update Workshop in Washington, D.C., bringing together experts from academia, industry, and the US Food and Drug Administration (FDA). This article summarizes key topics discussed during the meeting, including diagnostic challenges, emerging assessment methods, and trial endpoints. The D3‐creatine dilution technique was highlighted as a promising tool for evaluating muscle mass. Additionally, the workshop addressed variability in computed tomography‐based lumbar skeletal muscle index measurements, emphasizing sources of variation at the instrument, imaging, and reader levels, as well as biological and clinical fluctuations. Discussions also focused on clinical trial endpoints for sarcopenia, particularly validated physical performance measures such as the Short Physical Performance Battery (SPPB), habitual gait speed, stair‐climb tests, and the 6‐min walk test. Furthermore, novel therapeutic approaches were explored, including 20‐hydroxyecdysone, enobosarm, anamorelin, ponsegromab, and nutritional supplementation, alongside broader strategies targeting myostatin‐activin signalling inhibition and Akt pathway activation. During the meeting, it was made clear that from a regulatory treatment development standpoint, clinically meaningful changes in patient‐reported outcomes, physical function and/or morbidity/mortality need to be shown. If the latter is not an efficacy endpoint, safety needs to be documented. Given that the population that may be addressed in aging associated sarcopenia is vast, the safety requirement standards applied for studies may be equivalent to those of studies in type 2 diabetes mellitus. Some argued at the meeting that this would make study programs so large that from an economic standpoint only therapies that significantly impact on morbidity/mortality outcomes have a chance to be considered commercially feasible for development.

2025-05-01·ANNALS OF INTERNAL MEDICINE

Oncology: What You May Have Missed in 2024

Review

作者: Al Maqrashi, Zainab Ali Amer ; Dotan, Efrat ; Siddiqui, Zeba ; Chan, Sze Wah Samuel

Over the past 5 decades, substantial advances in oncology have reshaped cancer care, reflecting the dynamic role of internal medicine physicians in patients' journey from screening to diagnosis, treatment, and surveillance. This review highlights 10 landmark studies from 2024 that address emerging therapies and evolving clinical standards. Immunotherapy remains a central focus, with checkpoint inhibitors redefining the management of solid tumors and showing expanded applications across disease sites and earlier stages of disease. Targeted therapies and antibody-drug conjugates, including trastuzumab deruxtecan and enfortumab vedotin, are enhancing precision treatment options in metastatic cancer. Meanwhile, advances in supportive care, such as magnetic resonance imaging-guided prostate cancer screening, ponsegromab for cachexia, and celiac plexus radiosurgery for pain, show enhanced symptom management and quality of life for patients. These innovations highlight the critical role of multidisciplinary approaches, where internal medicine physicians contribute to co-management and toxicity monitoring, ultimately optimizing patient care. By staying current with these developments, internal medicine physicians are positioned to navigate complex oncologic care, ensuring that the benefits of novel therapies are maximized while mitigating their challenges.

项与珀塞古单抗相关的新闻（医药）

2025-10-21

·生物云析

GDF15：从癌症恶病质“元凶”到抗癌新靶点，一篇说清它的多面角色

在癌症研究与治疗领域，生长分化因子15（GDF15）近年来已从一个鲜为人知的应激蛋白，跃升为肿瘤生物学和临床肿瘤学中备受瞩目的关键分子。它不仅是驱动癌症恶病质的核心因子，更在肿瘤的发生、发展、治疗抵抗和免疫调节中扮演着复杂而关键的角色。今天，我们将从机制到临床，全面解读这一“多面手”分子。 ________________________________________ 🔍 什么是GDF15？其生物学基础是什么？ GDF15，全称生长分化因子15，是转化生长因子-β（TGF-β）超家族中的一员。在生理状态下，它在胎盘组织中表达最高，而在大多数成体组织中表达极低。然而，在细胞应激（如DNA损伤、缺氧、内质网应激）、炎症及肿瘤发生过程中，其表达会急剧上调。 GDF15最初以前体蛋白（pro-GDF15）形式合成，经蛋白酶切割后形成具有生物活性的成熟二聚体。其唯一已知的高亲和力受体是GFRAL，后者主要分布在大脑后缘区和孤束核——这两个区域正是调控食欲和能量平衡的中枢。GDF15与GFRAL的结合会招募共受体RET，进而激活下游的AKT、ERK等信号通路，最终导致食欲抑制、体重下降和能量消耗增加。 ________________________________________ 🦠 GDF15在癌症中的“双重角色”与矛盾行为 GDF15在肿瘤微环境中的作用呈现出令人惊讶的“双向性”，其具体效应可能因肿瘤类型、分期和微环境而异。 ✅ 促肿瘤作用（多数情况下）： • 促进侵袭与转移：在结直肠癌、胃癌中，GDF15通过激活SMAD2/3、PI3K/AKT等通路，诱导上皮-间质转化（EMT），增强肿瘤细胞的迁移和侵袭能力。 • 诱导治疗抵抗： o 在结直肠癌中，它通过稳定转录因子Nrf2，增强肿瘤细胞的抗氧化能力，从而削弱奥沙利铂等化疗药物通过氧化应激诱导的细胞凋亡。 o 在乳腺癌中，GDF15通过介导HER2和p38 MAPK磷酸化，降低肿瘤细胞对曲妥珠单抗的敏感性。 • 驱动免疫逃逸：在非小细胞肺癌、胶质母细胞瘤中，高水平的GDF15与肿瘤内CD8+ T细胞浸润减少、调节性T细胞增多相关，造成“免疫沙漠”表型，导致免疫检查点抑制剂治疗失败。 ❗ 抑肿瘤作用（特定情境下）： • 少数研究报道，在结直肠癌和前列腺癌的某些模型中，GDF15表现出促进凋亡、抑制肿瘤生长的作用。这提示其功能具有高度的情境依赖性，背后的机制仍需深入探索。 ________________________________________ 📊 GDF15作为生物标志物的巨大潜力由于其在不同癌症中普遍高表达，GDF15作为一种无创液体活检标志物展现出巨大潜力。 ________________________________________ 🧬 GDF15在头颈癌中的特殊意义与临床启示头颈部肿瘤患者因肿瘤位置直接影响吞咽和进食，加之放化疗的副作用，是恶病质的极高危人群。GDF15在此类癌症中的作用尤为突出： • 驱动恶性进展：GDF15与转录因子EGR1形成正反馈循环，互相促进表达，共同推动肿瘤增殖、侵袭和去分化。 • 介导治疗抵抗：研究发现，GDF15能通过SMAD1通路清除放疗产生的活性氧，保护肿瘤细胞免于凋亡，从而导致放射抵抗。 • 动态监测价值：术前高GDF15水平与较差的5年生存率相关，而术后其水平是否下降可作为手术疗效和长期预后的动态监测指标。 ________________________________________ 🧪 靶向GDF15的治疗策略：从概念到临床针对GDF15-GFRAL轴的药物研发已成为癌症恶病质和肿瘤治疗的新前沿。 1. Ponsegromab(珀塞古单抗)： o 一款人源化单克隆抗体，可高效中和循环中的GDF15。 o 关键PROACC-1研究显示，在伴有恶病质的肺癌、胰腺癌和结直肠癌患者中，Ponsegromab治疗12周后能带来剂量依赖性的体重增加（最高剂量组平均增重>5%），并显著改善食欲和体力活动。 2. Visugromab (CTL-002)： o 另一款GDF15中和抗体，侧重于与免疫治疗的联合。 o 在GDFATHER试验中，Visugromab联合纳武利尤单抗，在对PD-1/PD-L1抑制剂已耐药的晚期实体瘤患者中，取得了约15%的客观缓解率，且部分响应持久超过1年，显示出“逆转”免疫耐药的能力。 3. 其他在研药物： o 如AZD8853、NCM120等也处于早期临床试验阶段，探索其在改善恶病质和直接抗肿瘤方面的潜力。 ________________________________________ 💡 展望、挑战与未来方向尽管前景广阔，但GDF15的临床转化仍面临多重挑战： • 生物标志物标准化：目前缺乏统一的GDF15检测阈值，其水平受年龄、肾功能、合并症等多种因素影响，限制了其独立应用的准确性。 • 长期安全性：GDF15在生理状态下参与应激保护和组织修复，长期抑制是否会干扰机体的正常应激反应、导致代谢紊乱，仍需大规模临床试验的长期随访来验证。 • 精准患者选择：需要更深入的生物标志物研究，以识别最可能从抗GDF15治疗中获益的患者亚群。未来，GDF15调控通路有望成为精准抗癌的重要一环。通过将其抑制剂与化疗、放疗、免疫治疗乃至其他靶向药物联用，我们或许不仅能有效缓解恶病质、改善患者生活质量，更能从根本上增敏抗肿瘤治疗，逆转耐药，从而延长患者的生存时间。 ________________________________________ 结语 GDF15的科研和临床历程，完美诠释了转化医学的真谛——从一个令人困扰的“恶病质元凶”，逐步演变为一个极具潜力的诊断标志物和治疗新靶点。随着更多转化研究和临床试验的推进，GDF15有望在未来的肿瘤综合治疗体系中占据关键地位，为实现“带瘤生存”甚至“治愈”的目标增添一份力量。 ________________________________________ 参考文献： 1. Filippini, D.M., et al. The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy. Biomedicines 2025, *13*, 1931. 2. Johnen, H., et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med. 2007. 3. Yang, L., et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med. 2017. 4. Groarke, J.D., et al. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024. 5. Melero, I., et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025. ________________________________________ 声明：本文由专业医学文献内容支持，经AI辅助进行信息整合、翻译与编辑而成，旨在进行医学知识科普。文中所涉及的治疗方案均处于研究阶段，不能替代专业医疗建议。具体诊断与治疗请务必遵从主治医师的指导。

免疫疗法临床结果

2025-10-17

·FierceBiotech

ESMO: Pfizer sees year-long weight gain in cancer patients with wasting condition

Patients who received a placebo in the original 24-week portion of the study showed a stabilization of their weight once moved across to the open-label extension. \n For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a wasting syndrome.The syndrome, known medically as cachexia, is estimated to affect up to 80% of people with advanced cancer. As well as negatively affecting quality of life, the condition is thought to directly cause up to 30% of cancer deaths because muscle loss leads to heart or respiratory failure. In people with cachexia, GDF-15 is elevated and high levels of the cytokine are associated with poor outcomes.A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four weeks to a body weight gain of 3 kg at 12 weeks when compared to placebo. At the ESMO Congress 2025, the pharma has brought one-year data showing that these benefits were maintained over 12 months.Specifically, of the 117 patients with either non-small cell lung cancer, colorectal cancer or pancreatic cancer who moved into the 12-month, open-label extension part of the trial, the average weight gain was 2.7 kg at Week 24, 4.4 kg at Week 52 and 5.2 kg at Week 64.Patients who received a placebo in the original 24-week portion of the study showed a stabilization of their weight once moved across to the open-label extension. However, Pfizer noted in its ESMO abstract that the weight gain for these individuals was less than for those who received ponsegromab from the start. The drug continued to be safe and well-tolerated during the study’s extension, with no new safety signals, Pfizer noted.Aside from cachexia, Pfizer had also been investigating ponsegromab as a treatment for heart failure, but the company announced in February that it had discontinued this phase 2 work.

临床2期临床结果

2025-07-01

·药研网

GDF15崛起：能否成为继PD-1、GLP-1之后的“超级靶点”？

阅读导览前言GDF15靶点简介GDF15介导的信号通路“一靶多病”的治疗潜力GDF15在研格局总结与展望前言癌症恶病质（Cancer Cachexia）是一种常见且高度致残的癌症并发症，典型表现包括体重显著下降、骨骼肌丧失、食欲减退以及体力活动能力减弱，严重影响患者生活质量与生存预后。然而，长期以来该领域缺乏有效治疗手段。近日，《新英格兰医学杂志》发表了一项关于Ponsegromab（珀塞古单抗）的II期临床研究结果，为这一临床难题带来了新的突破。Ponsegromab是一种靶向GDF15的单克隆抗体，通过阻断GDF15通路，有望改善癌症恶病质相关的体重和肌肉流失，初步数据显示其在提高患者体重、改善食欲和身体功能方面表现出积极疗效，为癌症患者带来新的治疗希望。图源：The New England journal of MedicineGDF15靶点简介生长分化因子15（GDF15），又称巨噬细胞抑制细胞因子（MIC-1），是一种应激诱导型分泌蛋白，以25 kDa二聚体形式循环，由两个含112个氨基酸的多肽链经二硫键连接组成。GDF15在正常生理条件下表达水平较低，主要在肝、肾、心、肺等器官受到损伤或细胞应激时上调表达。近年来研究发现，GDF15在炎症调节、组织修复、代谢紊乱和细胞应激等生理及病理过程中均发挥关键作用，且其表达可由多种应激因子（如细胞损伤、氧化应激、抗糖尿病药物二甲双胍等）诱导上升。Figure.Structure of GDF-15. [2]GDF15介导的信号通路GDF15通过与其唯一已知受体GFRAL（胶质细胞源性神经营养因子家族α样受体）结合，形成配体-受体复合物，并招募辅助受体RET，从而激活一系列下游信号通路，包括RET、AKT、ERK和PLC-γ1等通路。该受体主要表达于延髓的孤束核区，GDF15-GFRAL通路因此在调控食欲、能量代谢、体重控制等方面发挥重要作用，并在心血管疾病、非酒精性脂肪肝等代谢类疾病中展现出潜在干预价值。Figure. Intracellular signaling pathways.[3]吉满生物基于前沿研究与市场需求，创新推出GDF15药物研发全流程解决方案，涵盖稳定表达细胞系、高灵敏度报告基因细胞系及高纯度抗体蛋白产品系列，为抗体药物体外药效评估提供精准工具，高效助力临床前研究及IND申报。（咨询吉满客服联系同微信：18916119826）“一靶多病”的治疗潜力肿瘤免疫逃逸：破解“冷肿瘤”的新钥匙GDF15在肿瘤微环境中高表达，抑制树突状细胞成熟、T细胞活化及浸润，帮助肿瘤逃避免疫监视。其“胎盘式免疫屏障”机制也被肿瘤细胞利用，导致免疫治疗耐药。靶向GDF15有望打破免疫抑制，增强PD-1/PD-L1疗法效果，为冷肿瘤患者提供新解法。改善癌症恶病质的潜力靶点GDF15是癌症恶病质的驱动因子之一。这类代谢综合征在50%~80%的癌症患者中出现，表现为厌食、体重骤降、肌肉和脂肪萎缩，严重影响生存质量和治疗耐受性。当前，靶向抗体GDF15的单抗Ponsegromab等正在开发，已显示出改善体重和身体功能的初步效果，为肿瘤支持治疗提供新路径。肥胖与糖尿病：继GLP-1后的中枢减重新靶点2017年前后，医学界发现了GDF15在肥胖治疗领域的潜力，礼来、诺和诺德和强生三家制药巨头同时在Nature Medicine明确指出GFRAL是GDF15的高亲和力受体，在减少摄食和降低体重机制中发挥着核心作用。这是科学家们首次确定GDF15调节体重的核心机制和关键受体，为肥胖和Ⅱ型糖尿病的治疗提供了绝佳的靶点。2023年6月28日，加拿大McMaster大学Dr. Gregory Steinberg课题组的王冬冬博士领导的GDF15研究项目在Nature上发表成果，系统阐释了GDF15通过提高肌肉能量消耗发挥减重作用的机制。Figure.连接GDF15与GFRAL和肾上腺素能受体的生物回路的机制图，以在热量限制期间维持肌肉的能量消耗[4]NAFLD与心血管疾病：炎症与代谢调控新窗口GDF15在非酒精性脂肪肝中可改善肝脏代谢、减轻炎症；同时作为心血管事件的应激标志物，也具备早期诊断与干预潜力，正在成为慢病管理领域的新焦点。GDF15靶点在研格局在全球范围内，GDF-15靶向药物的开发还处于较早期阶段，药物类型以单抗为主，最高临床阶段为临床II期，包括CatalYm的Visugromab、辉瑞的ponsegromab，NGM Bio的NGM120。数据来源：药研网辉瑞抗GDF15单抗Ponsegromab去年9月，辉瑞在欧洲肿瘤内科学会（ESMO）年会上公布Ponsegromab在临床II期研究中的积极结果：在所有测试的剂量中，ponsegromab组均达到了体重相对于基线的变化，与安慰剂相比，在12周时评估的最高剂量下体重平均增加5.6%；ponsegromab在所有剂量水平下均被认为安全且耐受性良好的，而且在测试的最高剂量下，患者食欲和恶病质症状、身体活动和肌肉质量较基线有所改善。按照辉瑞此前披露的计划，Ponsegromab预计在2025年推进III期临床试验；2022年底，Ponsegromab在国内也获批临床，成为国内首款获批临床的GDF15单抗。CatalYm的VisugromabVisugromab可中和肿瘤衍生的GDF-15，是一种局部作用的免疫抑制剂，可促进免疫疗法耐药性。此前在2024年ASCO年会上公布了1期临床研究结果，使用 Visugromab 中和 GDF-15 可逆转关键的癌症耐药机制，通过重新激活免疫细胞和肿瘤浸润来恢复有效的抗肿瘤反应。Visugromab 在临床1期试验中已展现出良好的安全性，目前正在针对多种实体瘤适应症开展临床2期研究。劲方医药GDF15/IL-6双抗GFS202AGFS202A为拮抗性双特异性抗体，是全球首个恶病质双抗疗法及GDF15/IL-6双抗产品，也是国内首个进入临床的恶病质靶向疗法及GDF-15抗体类药物。今年3月，劲方医药宣布，GFS202A针对肿瘤恶病质前期及恶病质期患者开展一项开放标签、多中心的I期临床研究试验申请获得国家药品监督管理局批准。此外，针对GDF-15靶点的其他药物类型有纳米抗体、融合蛋白、重组蛋白和小分子化药，适应症多为肥胖。其中由美国强生开发小分子药物JNJ-9090处于临床1期阶段，这是一款GDF-15调节剂，其作用机制主要是通过激活GFRAL受体来促进产热和脂解。这些靶向GDF-15的临床前阶段药物种类丰富，也为未来的药物研发提供了积极的信号。总结及展望GDF15凭借其在免疫调节与代谢控制中的“双重功能”，正在成为肿瘤治疗、代谢疾病干预和慢性病控制的共同靶点。从癌症免疫耐药与恶病质，到肥胖、糖尿病和NAFLD，靶向GDF15不仅打通了多个疾病路径，也为未来多靶点协同治疗打开全新窗口。随着Ponsegromab等靶向药物推进临床，GDF15有望成为“免疫+代谢”精准医学新时代的关键分子。吉满生物吉满生物基于前沿研究与市场需求，创新推出GDF15药物研发全流程解决方案，涵盖稳定表达细胞系、高灵敏度报告基因细胞系及高纯度抗体蛋白产品系列。产品列表数据展示GM-C06718 H_GDF15 Reporter 293 Cell Line使用Recombinant Human GDF-15蛋白激活验证结果H_GDF15 Reporter 293 Cell Line使用Recombinant Human GDF-15蛋白激活验证结果GM-C19363 Mouse_GDF15 Reporter 293 Cell Line使用Recombinant Mouse GDF-15蛋白激活验证结果GM-C28579 H_GDF15 Reporter 293 DDX35TM Cell Line使用Recombinant Human GDF-15蛋白各代次稳定性验证结果H_GDF15 Reporter 293 DDX35TM Cell Line使用Recombinant Human GDF-15蛋白高低代次三重复验证结果GM-87627RP Human GDF15 Protein; His Tag ELISA验证联系我们吉满生物(Genomeditech)成立于2011年，是专业从事生物科技服务和前沿技术研发的高新技术企业。吉满生物专注为生物药开发赋能，自主创立了国内知名的细胞系品牌-DDXCELL，目前已布局近400个热门靶向药靶点，超1000株现货单克隆细胞系，涵盖GPCR、细胞因子、免疫检查点、TAA等多领域，做到进口细胞的国产替代。此外，吉满生物还可在药物研发进程中提供一系列抗体、蛋白产品，旨在为客户提供高效的研发工具和解决方案!扫码咨询扫码找现货参考文献：1. Dufour I, Bindels LB, Goffin E. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2025 Mar 6;392(10):1035. doi: 10.1056/NEJMc2500502. PMID: 40043243.2. Delrue, C., et al., Growth differentiation factor 15 (GDF-15) in kidney diseases. Adv Clin Chem, 2023. 114: p. 1-46.3. Adela, R. and S.K. Banerjee, GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res, 2015. 2015: p. 4908424. Wang, D., Townsend, L.K., DesOrmeaux, G.J. et al. GDF15 promotes weight loss by enhancing energy expenditure in muscle. Nature 619, 143–150 (2023). https://doi.org/10.1038/s41586-023-06249-45. Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14. PMID: 39282907.6. https://www.esmo.org/oncology-news/inhibition-of-gdf-15-with-ponsegromab-results-in-increased-weight-gain-and-overall-activity-level-and-reduced-cancer-cachexia-symptoms7. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.25138. https://mp.weixin.qq.com/s/Nh4ShQqQx-U_-CphXoskgg

临床申请免疫疗法临床2期

100 项与珀塞古单抗相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶病质	临床3期	美国	Pfizer Inc.	2025-10-03
恶病质	临床3期	日本	Pfizer Inc.	2025-10-03
恶病质	临床3期	澳大利亚	Pfizer Inc.	2025-10-03
恶病质	临床3期	以色列	Pfizer Inc.	2025-10-03
疲劳	临床3期	美国	Pfizer Inc.	2025-10-03
疲劳	临床3期	日本	Pfizer Inc.	2025-10-03
疲劳	临床3期	澳大利亚	Pfizer Inc.	2025-10-03
疲劳	临床3期	以色列	Pfizer Inc.	2025-10-03
转移性胰腺导管腺癌	临床3期	美国	Pfizer Inc.	2025-10-03
转移性胰腺导管腺癌	临床3期	日本	Pfizer Inc.	2025-10-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05546476 (NCT05546476 \| PROACC-1 \| ###DELETE, CTgov)	临床2期	疲劳 \| 恶病质 \| 厌食症 ... 更多	187	placebo+Ponsegromab (Part A: Placebo)	餘遞淵製蓋遞膚齋獵鹽(繭齋鬱夢鹽獵廠鹽鹹繭) = 鏇鹹遞壓構鹹遞廠鏇築壓鬱構夢壓獵繭構窪範 (蓋獵觸糧鑰顧遞醖艱齋, 壓願製觸糧齋蓋艱糧鑰 ~ 選廠遞蓋窪鹹衊鏇鏇顧) 更多	-	2025-04-29
				Ponsegromab (Part A: Ponsegromab 100 mg)	餘遞淵製蓋遞膚齋獵鹽(繭齋鬱夢鹽獵廠鹽鹹繭) = 構簾製壓積繭夢壓獵壓壓鬱構夢壓獵繭構窪範 (蓋獵觸糧鑰顧遞醖艱齋, 廠鹹衊鏇窪鹽選蓋艱窪 ~ 遞壓觸願遞憲遞夢壓願) 更多
NCT05546476 (Pubmed \| N Engl J Med)	临床2期	恶病质 GDF-15	187	Ponsegromab 100 mg	夢鹹繭齋艱衊願鹽構鑰(廠顧築廠遞鏇壓艱淵醖) = 蓋醖鏇夢膚廠糧鏇鬱憲簾壓簾糧艱遞獵膚夢艱 (觸願顧憲鬱壓獵範觸獵, 0.37 ~ 2.25)	积极	2024-12-19
				Ponsegromab 200 mg	夢鹹繭齋艱衊願鹽構鑰(廠顧築廠遞鏇壓艱淵醖) = 鹹艱夢網鬱膚鬱鬱窪糧簾壓簾糧艱遞獵膚夢艱 (觸願顧憲鬱壓獵範觸獵, 0.92 ~ 2.97)
NCT05685264 (CTgov)	临床1期	-	18	Ponsegromab (Cohort 1: Ponsegromab 100 mg)	範餘襯顧襯膚構艱構選(積淵鬱蓋餘糧衊齋餘鹹) = 遞夢積顧選壓選製鏇壓網齋製鹽餘築淵夢築窪 (構鬱構鹹遞願衊憲鹹艱, 58) 更多	-	2024-10-01
				Ponsegromab (Cohort 2: Ponsegromab 400 mg)	範餘襯顧襯膚構艱構選(積淵鬱蓋餘糧衊齋餘鹹) = 蓋顧餘繭膚顧築鑰網廠網齋製鹽餘築淵夢築窪 (構鬱構鹹遞願衊憲鹹艱, 59) 更多
NCT04803305 (CTgov)	临床1期	卵巢癌 \| 疲劳 \| 恶病质 ... 更多	18	placebo (Placebo)	憲願鬱獵蓋積鹹窪壓衊(餘繭窪繭鹽積襯衊襯顧) = 積壓簾蓋齋鹹遞壓築簾願衊選醖醖壓範製淵遞 (鏇襯構蓋淵膚膚願襯顧, 憲獵醖襯齋鏇衊衊積範 ~ 憲醖糧鏇觸艱積選蓋遞) 更多	-	2024-01-12
				PF-06946860 (PF-06946860 200mg Q3W)	憲願鬱獵蓋積鹹窪壓衊(餘繭窪繭鹽積襯衊襯顧) = 網窪築遞廠蓋膚淵願艱願衊選醖醖壓範製淵遞 (鏇襯構蓋淵膚膚願襯顧, 願製襯積艱選鑰遞淵醖 ~ 選鑰膚積壓築醖觸蓋淵) 更多
NCT04299048 (CTgov)	临床1期	不能切除性胰腺癌 \| 恶病质 \| 非小细胞肺癌 ... 更多	11	PF-06946860	顧夢網選夢醖觸蓋願廠 = 觸網繭齋選築獵製選築鬱窪繭遞築憲鏇鑰範窪 (憲糧鏇鹹夢觸壓築繭構, 艱襯積獵醖繭網選構窪 ~ 顧鬱糧選蓋製鑰獵簾壓) 更多	-	2023-12-14
NCT04299048 (AACR2023) 人工标引	临床1期	恶病质 \| 肿瘤	10	ponsegromab	構構餘鑰繭糧艱醖蓋齋(網獵繭網構蓋餘鑰壓構) = 壓願製衊淵鹹觸鏇窪鬱窪顧齋遞鏇窪廠築網網 (顧鏇餘範製遞艱觸齋鹹 )	积极	2023-04-14